Gene expression in the Parkinson's disease brain

Brain Research Bulletin

Volumn 88, Issue 4, 2012, Pages 302-312

  Lewis, Patrick A ^a   Cookson, Mark R ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Gene expression; Genome wide; Microarray; Neuropathology; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CANNABINOID 2 RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HISTONE H3; PROTEASOME; TAU PROTEIN; UBIQUITIN;

CELL ISOLATION; CELL SURVIVAL; CEREBELLUM; DEGENERATION; DEMENTIA; DISEASE SEVERITY; ELECTRON TRANSPORT; GENE DOSAGE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC VARIABILITY; HIPPOCAMPUS; LASER CAPTURE MICRODISSECTION; MIDDLE FRONTAL GYRUS; OCCIPITAL CORTEX; PARKINSON DISEASE; PARKINSONISM; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PUTAMEN; REVIEW; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; TRANSCRIPTION REGULATION; UBIQUITINATION;

BRAIN; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; PARKINSON DISEASE;

EID: 84862185980     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2011.11.016     Document Type: Review

References (135)

1. Aarsland D., Beyer M.K., Kurz M.W. Dementia in Parkinson's disease. Curr. Opin. Neurol. 2008, 21:676-682.
2. Aarsland D., Kurz M.W. The epidemiology of dementia associated with Parkinson's disease. Brain Pathol. 2010, 20:633-639.
3. Adler C.H., Connor D.J., Hentz J.G., Sabbagh M.N., Caviness J.N., Shill H.A., Noble B., Beach T.G. Incidental Lewy body disease: clinical comparison to a control cohort. Mov. Disord. 2010, 25:642-646.
4. Affymetrix, . http://www.affymetrix.com/browse/products.jsp?productId=131452&navMode=34000&navAction=jump&aId=productsNav-1_1.
5. Affymetrix, . http://www.affymetrix.com/browse/products.jsp?productId=131537&categoryId=35760-1_1.
6. Baldereschi M., Di Carlo A., Rocca W.A., Vanni P., Maggi S., Perissinotto E., Grigoletto F., Amaducci L., Inzitari D. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000, 55:1358-1363.
7. Barrachina M., Castano E., Ferrer I., TaqMan PCR assay in the control of RNA normalization in human post-mortem brain tissue. Neurochem. Int. 2006, 49:276-284.
8. Beach T.G., Sue L.I., Walker D.G., Roher A.E., Lue L., Vedders L., Connor D.J., Sabbagh M.N., Rogers J. The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank 2008, 9:229-245.
9. Bonner R.F., Emmert-Buck M., Cole K., Pohida T., Chuaqui R., Goldstein S., Liotta L.A. Laser capture microdissection: molecular analysis of tissue. Science 1997, 278:1481-1483.
10. Botta-Orfila T., Tolosa E., Gelpi E., Sanchez-Pla A., Marti M.J., Valldeoriola F., Fernandez M., Carmona F., Ezquerra M. Microarray expression analysis in idiopathic and LRRK2-associated Parkinson's disease. Neurobiol. Dis. 2011.
11. Braak H., Braak E. Pathoanatomy of Parkinson's disease. J. Neurol. 2000, 247(2):II3-II10.
12. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
13. Burke R.E., Dauer W.T., Vonsattel J.P. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann. Neurol. 2008, 64:485-491.
14. Burton P.R., Hansell A.L., Fortier I., Manolio T.A., Khoury M.J., Little J., Elliott P. Size matters: just how big is BIG? Quantifying realistic sample size requirements for human genome epidemiology. Int. J. Epidemiol. 2009, 38:263-273.
15. Cantuti-Castelvetri I., Keller-McGandy C., Bouzou B., Asteris G., Clark T.W., Frosch M.P., Standaert D.G. Effects of gender on nigral gene expression and Parkinson disease. Neurobiol. Dis. 2007, 26:606-614.
16. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., Destee A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
17. Chevyreva I., Faull R.L., Green C.R., Nicholson L.F. Assessing RNA quality in postmortem human brain tissue. Exp. Mol. Pathol. 2008, 84:71-77.
18. Chiba K., Trevor A., Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 1984, 120:574-578.
19. Chiba K., Trevor A.J., Castagnoli N. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem. Biophys. Res. Commun. 1985, 128:1228-1232.
20. Clark T.A., Schweitzer A.C., Chen T.X., Staples M.K., Lu G., Wang H., Williams A., Blume J.E. Discovery of tissue-specific exons using comprehensive human exon microarrays. Genome Biol. 2007, 8:R64.
21. Clayton D.G., Walker N.M., Smyth D.J., Pask R., Cooper J.D., Maier L.M., Smink L.J., Lam A.C., Ovington N.R., Stevens H.E., Nutland S., Howson J.M., Faham M., Moorhead M., Jones H.B., Falkowski M., Hardenbol P., Willis T.D., Todd J.A. Population structure, differential bias and genomic control in a large-scale, case-control association study. Nat. Genet. 2005, 37:1243-1246.
22. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:571-576.
23. Cookson W., Liang L., Abecasis G., Moffatt M., Lathrop M. Mapping complex disease traits with global gene expression. Nat. Rev. Genet. 2009, 10:184-194.
24. Devine M.J., Kaganovich A., Ryten M., Mamais A., Trabzuni D., Manzoni C., McGoldrick P., Chan D., Dillman A., Zerle J., Horan S., Taanman J.W., Hardy J., Marti-Masso J.F., Healey D., Schapira A.H., Wolozin B., Bandopadhyay R., Cookson M.R., van der Brug M.P., Lewis P.A. Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue. PLoS One 2011, 6:e22489.
25. Devine M.J., Ryten M., Vodicka P., Thomson A.J., Burdon T., Houlden H., Cavaleri F., Nagano M., Drummond N.J., Taanman J.W., Schapira A.H., Gwinn K., Hardy J., Lewis P.A., Kunath T. Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat. Commun. 2011, 2:440.
26. Dickson D.W. Neuropathology of Alzheimer's disease and other dementias. Clin. Geriatr. Med. 2001, 17:209-228.
27. Dickson D.W., Braak H., Duda J.E., Duyckaerts C., Gasser T., Halliday G.M., Hardy J., Leverenz J.B., Del Tredici K., Wszolek Z.K., Litvan I. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 2009, 8:1150-1157.
28. Double K.L., Reyes S., Werry E.L., Halliday G.M. Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions?. Prog. Neurobiol. 2010, 92:316-329.
29. Durinck S. Pre-processing of microarray data and analysis of differential expression. Methods Mol. Biol. 2008, 452:89-110.
30. Duyckaerts C., Delatour B., Potier M.C. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009, 118:5-36.
31. Efron B., Tibshirani R. Empirical bayes methods and false discovery rates for microarrays. Genet. Epidemiol. 2002, 23:70-86.
32. Emmert-Buck M.R., Bonner R.F., Smith P.D., Chuaqui R.F., Zhuang Z., Goldstein S.R., Weiss R.A., Liotta L.A. Laser capture microdissection. Science 1996, 274:998-1001.
33. Ervin J.F., Heinzen E.L., Cronin K.D., Goldstein D., Szymanski M.H., Burke J.R., Welsh-Bohmer K.A., Hulette C.M. Postmortem delay has minimal effect on brain RNA integrity. J. Neuropathol. Exp. Neurol. 2007, 66:1093-1099.
34. Farber C.R., Lusis A.J. Integrating global gene expression analysis and genetics. Adv. Genet. 2008, 60:571-601.
35. Fearnley J.M., Lees A.J., Ageing Parkinson's disease: Substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
36. Ferrer I., Martinez A., Boluda S., Parchi P., Barrachina M. Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell Tissue Bank 2008, 9:181-194.
37. Franz H., Ullmann C., Becker A., Ryan M., Bahn S., Arendt T., Simon M., Paabo S., Khaitovich P. Systematic analysis of gene expression in human brains before and after death. Genome Biol. 2005, 6:R112.
38. Frigerio R., Fujishiro H., Ahn T.B., Josephs K.A., Maraganore D.M., Delledonne A., Parisi J.E., Klos K.J., Boeve B.F., Dickson D.W., Ahlskog J.E. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies?. Neurobiol. Aging 2009.
39. Fuchs J., Nilsson C., Kachergus J., Munz M., Larsson E.M., Schule B., Langston J.W., Middleton F.A., Ross O.A., Hulihan M., Gasser T., Farrer M.J. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007, 68:916-922.
40. Gandhi S., Wood N.W. Genome-wide association studies: the key to unlocking neurodegeneration?. Nat. Neurosci. 2010, 13:789-794.
41. Gibbs J.R., van der Brug M.P., Hernandez D.G., Traynor B.J., Nalls M.A., Lai S.L., Arepalli S., Dillman A., Rafferty I.P., Troncoso J., Johnson R., Zielke H.R., Ferrucci L., Longo D.L., Cookson M.R., Singleton A.B. Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet. 2010, 6:e1000952.
42. Goh K.I., Cusick M.E., Valle D., Childs B., Vidal M., Barabasi A.L. The human disease network. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:8685-8690.
43. Grunblatt E., Mandel S., Jacob-Hirsch J., Zeligson S., Amariglo N., Rechavi G., Li J., Ravid R., Roggendorf W., Riederer P., Youdim M.B. Gene expression profiling of parkinsonian Substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural Transm. 2004, 111:1543-1573.
44. Grunblatt E., Zander N., Bartl J., Jie L., Monoranu C.M., Arzberger T., Ravid R., Roggendorf W., Gerlach M., Riederer P. Comparison analysis of gene expression patterns between sporadic Alzheimer's and Parkinson's disease. J. Alzheimers Dis. 2007, 12:291-311.
45. Grunblatt E., Zehetmayer S., Jacob C.P., Muller T., Jost W.H., Riederer P. Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. J. Neural Transm. 2010, 117:1387-1393.
46. Hamza T.H., Zabetian C.P., Tenesa A., Laederach A., Montimurro J., Yearout D., Kay D.M., Doheny K.F., Paschall J., Pugh E., Kusel V.I., Collura R., Roberts J., Griffith A., Samii A., Scott W.K., Nutt J., Factor S.A., Payami H. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 2010, 42:781-785.
47. Hardingham G.E., Patani R., Baxter P., Wyllie D.J., Chandran S. Human embryonic stem cell-derived neurons as a tool for studying neuroprotection and neurodegeneration. Mol. Neurobiol. 2010, 42:97-102.
48. Hardy J. Genetic analysis of pathways to Parkinson disease. Neuron 2010, 68:201-206.
49. Hardy J., Lewis P., Revesz T., Lees A., Paisan-Ruiz C. The genetics of Parkinson's syndromes a critical review. Curr. Opin. Genet. Dev. 2009.
50. Harraz M.M., Dawson T.M., Dawson V.L. MicroRNAs in Parkinson's disease. J. Chem. Neuroanat. 2011, 42:127-130.
51. Harrison P.J., Heath P.R., Eastwood S.L., Burnet P.W., McDonald B., Pearson R.C. The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins. Neurosci. Lett. 1995, 200:151-154.
52. Hauser M.A., Li Y.J., Takeuchi S., Walters R., Noureddine M., Maready M., Darden T., Hulette C., Martin E., Hauser E., Xu H., Schmechel D., Stenger J.E., Dietrich F., Vance J. Genomic convergence: identifying candidate genes for Parkinson's disease by combining serial analysis of gene expression and genetic linkage. Hum. Mol. Genet. 2003, 12:671-677.
53. Hauser M.A., Li Y.J., Xu H., Noureddine M.A., Shao Y.S., Gullans S.R., Scherzer C.R., Jensen R.V., McLaurin A.C., Gibson J.R., Scott B.L., Jewett R.M., Stenger J.E., Schmechel D.E., Hulette C.M., Vance J.M. Expression profiling of Substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with Parkinsonism. Arch. Neurol. 2005, 62:917-921.
54. Hawkins R.D., Hon G.C., Ren B. Next-generation genomics: an integrative approach. Nat. Rev. Genet. 2010, 11:476-486.
55. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
56. Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C., Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M., Joosse M., Kwon J.M., Nowotny P., Che L.K., Norton J., Morris J.C., Reed L.A., Trojanowski J., Basun H., Lannfelt L., Neystat M., Fahn S., Dark F., Tannenberg T., Dodd P.R., Hayward N., Kwok J.B., Schofield P.R., Andreadis A., Snowden J., Craufurd D., Neary D., Owen F., Oostra B.A., Hardy J., Goate A., van Swieten J., Mann D., Lynch T., Heutink P. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
57. Ikeuchi T., Kakita A., Shiga A., Kasuga K., Kaneko H., Tan C.F., Idezuka J., Wakabayashi K., Onodera O., Iwatsubo T., Nishizawa M., Takahashi H., Ishikawa A. Patients homozygous and heterozygous for SNCA duplication in a family with Parkinsonism and dementia. Arch. Neurol. 2008, 65:514-519.
58. Ioannidis J.P., Thomas G., Daly M.J., Validating augmenting and refining genome-wide association signals. Nat. Rev. Genet. 2009, 10:318-329.
59. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:2173-2177.
60. Kapur K., Xing Y., Ouyang Z., Wong W.H. Exon arrays provide accurate assessments of gene expression. Genome Biol. 2007, 8:R82.
61. Kehagia A.A., Barker R.A., Robbins T.W. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 2010, 9:1200-1213.
62. Kim J., Inoue K., Ishii J., Vanti W.B., Voronov S.V., Murchison E., Hannon G., Abeliovich A. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 2007, 317:1220-1224.
63. Kohler K., Bickeboller H. Case-control association tests correcting for population stratification. Ann. Hum. Genet. 2006, 70:98-115.
64. Lander E.S. Initial impact of the sequencing of the human genome. Nature 2011, 470:187-197.
65. Langerveld A.J., Mihalko D., DeLong C., Walburn J., Ide C.F. Gene expression changes in postmortem tissue from the rostral pons of multiple system atrophy patients. Mov. Disord. 2007, 22:766-777.
66. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
67. Langston J.W., Ballard P.A. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N. Engl. J. Med. 1983, 309:310.
68. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
69. Li Y.J., Scott W.K., Hedges D.J., Zhang F., Gaskell P.C., Nance M.A., Watts R.L., Hubble J.P., Koller W.C., Pahwa R., Stern M.B., Hiner B.C., Jankovic J., Allen F.A., Goetz C.G., Mastaglia F., Stajich J.M., Gibson R.A., Middleton L.T., Saunders A.M., Scott B.L., Small G.W., Nicodemus K.K., Reed A.D., Schmechel D.E., Welsh-Bohmer K.A., Conneally P.M., Roses A.D., Gilbert J.R., Vance J.M., Haines J.L., Pericak-Vance M.A. Age at onset in two common neurodegenerative diseases is genetically controlled. Am. J. Hum. Genet. 2002, 70:985-993.
70. Lippa C.F., Duda J.E., Grossman M., Hurtig H.I., Aarsland D., Boeve B.F., Brooks D.J., Dickson D.W., Dubois B., Emre M., Fahn S., Farmer J.M., Galasko D., Galvin J.E., Goetz C.G., Growdon J.H., Gwinn-Hardy K.A., Hardy J., Heutink P., Iwatsubo T., Kosaka K., Lee V.M., Leverenz J.B., Masliah E., McKeith I.G., Nussbaum R.L., Olanow C.W., Ravina B.M., Singleton A.B., Tanner C.M., Trojanowski J.Q., Wszolek Z.K. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007, 68:812-819.
71. Lockhart D.J., Dong H., Byrne M.C., Follettie M.T., Gallo M.V., Chee M.S., Mittmann M., Wang C., Kobayashi M., Horton H., Brown E.L. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat. Biotechnol. 1996, 14:1675-1680.
72. Lu L., Neff F., Alvarez-Fischer D., Henze C., Xie Y., Oertel W.H., Schlegel J., Hartmann A. Gene expression profiling of Lewy body-bearing neurons in Parkinson's disease. Exp. Neurol. 2005, 195:27-39.
73. Lu L., Neff F., Fischer D.A., Henze C., Hirsch E.C., Oertel W.H., Schlegel J., Hartmann A. Regional vulnerability of mesencephalic dopaminergic neurons prone to degenerate in Parkinson's disease: a post-mortem study in human control subjects. Neurobiol. Dis. 2006, 23:409-421.
74. Mardis E.R. A decade's perspective on DNA sequencing technology. Nature 2011, 470:198-203.
75. Matlin A.J., Clark F., Smith C.W. Understanding alternative splicing: towards a cellular code. Nat. Rev. Mol. Cell. Biol. 2005, 6:386-398.
76. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., Aarsland D., Arai H., Ballard C.G., Boeve B., Burn D.J., Costa D., Del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C.G., Gomez-Tortosa E., Halliday G., Hansen L.A., Hardy J., Iwatsubo T., Kalaria R.N., Kaufer D., Kenny R.A., Korczyn A., Kosaka K., Lee V.M., Lees A., Litvan I., Londos E., Lopez O.L., Minoshima S., Mizuno Y., Molina J.A., Mukaetova-Ladinska E.B., Pasquier F., Perry R.H., Schulz J.B., Trojanowski J.Q., Yamada M. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
77. Mellick G.D., Silburn P.A., Sutherland G.T., Siebert G.A. Exploiting the potential of molecular profiling in Parkinson's disease: current practice and future probabilities. Expert. Rev. Mol. Diagn. 2010, 10:1035-1050.
78. Miller D.W., Hague S.M., Clarimon J., Baptista M., Gwinn-Hardy K., Cookson M.R., Singleton A.B. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004, 62:1835-1838.
79. Minones-Moyano E., Porta S., Escaramis G., Rabionet R., Iraola S., Kagerbauer B., Espinosa-Parrilla Y., Ferrer I., Estivill X., Marti E. MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum. Mol. Genet. 2011, 20:3067-3078.
80. Monoranu C.M., Apfelbacher M., Grunblatt E., Puppe B., Alafuzoff I., Ferrer I., Al-Saraj S., Keyvani K., Schmitt A., Falkai P., Schittenhelm J., Halliday G., Kril J., Harper C., McLean C., Riederer P., Roggendorf W. pH measurement as quality control on human post mortem brain tissue: a study of the BrainNet Europe consortium. Neuropathol. Appl. Neurobiol. 2009, 35:329-337.
81. Montgomery S.B., Sammeth M., Gutierrez-Arcelus M., Lach R.P., Ingle C., Nisbett J., Guigo R., Dermitzakis E.T. Transcriptome genetics using second generation sequencing in a Caucasian population. Nature 2010, 464:773-777.
82. Moran L.B., Duke D.C., Deprez M., Dexter D.T., Pearce R.K., Graeber M.B. Whole genome expression profiling of the medial and lateral Substantia nigra in Parkinson's disease. Neurogenetics 2006, 7:1-11.
83. Nadon R., Shoemaker J. Statistical issues with microarrays: processing and analysis. Trends Genet. 2002, 18:265-271.
84. Nalls M.A., Plagnol V., Hernandez D.G., Sharma M., Sheerin U.M., Saad M., Simon-Sanchez J., Schulte C., Lesage S., Sveinbjornsdottir S., Stefansson K., Martinez M., Hardy J., Heutink P., Brice A., Gasser T., Singleton A.B., Wood N.W. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377:641-649.
85. Noureddine M.A., Li Y.J., van der Walt J.M., Walters R., Jewett R.M., Xu H., Wang T., Walter J.W., Scott B.L., Hulette C., Schmechel D., Stenger J.E., Dietrich F., Vance J.M., Hauser M.A. Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the Substantia nigra. Mov. Disord. 2005, 20:1299-1309.
86. O'Sullivan S.S., Massey L.A., Williams D.R., Silveira-Moriyama L., Kempster P.A., Holton J.L., Revesz T., Lees A.J. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 2008, 131:1362-1372.
87. Pakkenberg H., Brody H. The number of nerve cells in the Substantia nigra in paralysis agitans. Acta Neuropathol. 1965, 5:320-324.
88. Pan Q., Shai O., Lee L.J., Frey B.J., Blencowe B.J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 2008, 40:1413-1415.
89. Papapetropoulos S., Ffrench-Mullen J., McCorquodale D., Qin Y., Pablo J., Mash D.C. Multiregional gene expression profiling identifies MRPS6 as a possible candidate gene for Parkinson's disease. Gene Exp. 2006, 13:205-215.
90. Papapetropoulos S., Shehadeh L., McCorquodale D. Optimizing human post-mortem brain tissue gene expression profiling in Parkinson's disease and other neurodegenerative disorders: from target fishing to translational breakthroughs. J. Neurosci. Res. 2007, 85:3013-3024.
91. Polanski A., Polanska J., Jarzab M., Wiench M., Jarzab B. Application of Bayesian networks for inferring cause-effect relations from gene expression profiles of cancer versus normal cells. Math. Biosci. 2007, 209:528-546.
92. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
93. Preece P., Cairns N.J. Quantifying mRNA in postmortem human brain: influence of gender, age at death, postmortem interval, brain pH, agonal state and inter-lobe mRNA variance. Brain Res. Mol. Brain Res. 2003, 118:60-71.
94. Riess O., Kruger R., Schulz J.B. Spectrum of phenotypes and genotypes in Parkinson's disease. J. Neurol. 2002, 249(Suppl 3). III/15-20.
95. Ruetze M., Lochner K., Gallinat S., Knott A. Analysis of tissue-specific gene expression using laser capture microdissection. Methods Mol. Biol. 2010, 585:183-192.
96. Saad M., Lesage S., Saint-Pierre A., Corvol J.C., Zelenika D., Lambert J.C., Vidailhet M., Mellick G.D., Lohmann E., Durif F., Pollak P., Damier P., Tison F., Silburn P.A., Tzourio C., Forlani S., Loriot M.A., Giroud M., Helmer C., Portet F., Amouyel P., Lathrop M., Elbaz A., Durr A., Martinez M., Brice A. Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Hum. Mol. Genet. 2011, 20:615-627.
97. Sahin E., Colla S., Liesa M., Moslehi J., Muller F.L., Guo M., Cooper M., Kotton D., Fabian A.J., Walkey C., Maser R.S., Tonon G., Foerster F., Xiong R., Wang Y.A., Shukla S.A., Jaskelioff M., Martin E.S., Heffernan T.P., Protopopov A., Ivanova E., Mahoney J.E., Kost-Alimova M., Perry S.R., Bronson R., Liao R., Mulligan R., Shirihai O.S., Chin L., Depinho R.A. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011.
98. Satake W., Nakabayashi Y., Mizuta I., Hirota Y., Ito C., Kubo M., Kawaguchi T., Tsunoda T., Watanabe M., Takeda A., Tomiyama H., Nakashima K., Hasegawa K., Obata F., Yoshikawa T., Kawakami H., Sakoda S., Yamamoto M., Hattori N., Murata M., Nakamura Y., Toda T. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 2009, 41:1303-1307.
99. Scherzer C.R., Eklund A.C., Morse L.J., Liao Z., Locascio J.J., Fefer D., Schwarzschild M.A., Schlossmacher M.G., Hauser M.A., Vance J.M., Sudarsky L.R., Standaert D.G., Growdon J.H., Jensen R.V., Gullans S.R. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:955-960.
100. Schroeder A., Mueller O., Stocker S., Salowsky R., Leiber M., Gassmann M., Lightfoot S., Menzel W., Granzow M., Ragg T. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol. Biol. 2006, 7:3.
101. Scott W.K., Nance M.A., Watts R.L., Hubble J.P., Koller W.C., Lyons K., Pahwa R., Stern M.B., Colcher A., Hiner B.C., Jankovic J., Ondo W.G., Allen F.H., Goetz C.G., Small G.W., Masterman D., Mastaglia F., Laing N.G., Stajich J.M., Slotterbeck B., Booze M.W., Ribble R.C., Rampersaud E., West S.G., Gibson R.A., Middleton L.T., Roses A.D., Haines J.L., Scott B.L., Vance J.M., Pericak-Vance M.A. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 2001, 286:2239-2244.
102. Seeley W.W. Selective functional, regional, and neuronal vulnerability in frontotemporal dementia. Curr. Opin. Neurol. 2008, 21:701-707.
103. Shehadeh L.A., Yu K., Wang L., Guevara A., Singer C., Vance J., Papapetropoulos S. SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease. PLoS One 2010, 5:e9104.
104. Simon-Sanchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., Kruger R., Federoff M., Klein C., Goate A., Perlmutter J., Bonin M., Nalls M.A., Illig T., Gieger C., Houlden H., Steffens M., Okun M.S., Racette B.A., Cookson M.R., Foote K.D., Fernandez H.H., Traynor B.J., Schreiber S., Arepalli S., Zonozi R., Gwinn K., van der Brug M., Lopez G., Chanock S.J., Schatzkin A., Park Y., Hollenbeck A., Gao J., Huang X., Wood N.W., Lorenz D., Deuschl G., Chen H., Riess O., Hardy J.A., Singleton A.B., Gasser T. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
105. Simunovic F., Yi M., Wang Y., Macey L., Brown L.T., Krichevsky A.M., Andersen S.L., Stephens R.M., Benes F.M., Sonntag K.C. Gene expression profiling of Substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 2009, 132:1795-1809.
106. Simunovic F., Yi M., Wang Y., Stephens R., Sonntag K.C. Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease. PLoS One 2010, 5:e8856.
107. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
108. Soldner F., Hockemeyer D., Beard C., Gao Q., Bell G.W., Cook E.G., Hargus G., Blak A., Cooper O., Mitalipova M., Isacson O., Jaenisch R. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009, 136:964-977.
109. Song Y.J., Huang Y., Halliday G.M. Clinical correlates of similar pathologies in parkinsonian syndromes. Mov. Disord. 2011.
110. Spencer C.C., Plagnol V., Strange A., Gardner M., Paisan-Ruiz C., Band G., Barker R.A., Bellenguez C., Bhatia K., Blackburn H., Blackwell J.M., Bramon E., Brown M.A., Burn D., Casas J.P., Chinnery P.F., Clarke C.E., Corvin A., Craddock N., Deloukas P., Edkins S., Evans J., Freeman C., Gray E., Hardy J., Hudson G., Hunt S., Jankowski J., Langford C., Lees A.J., Markus H.S., Mathew C.G., McCarthy M.I., Morrison K.E., Palmer C.N., Pearson J.P., Peltonen L., Pirinen M., Plomin R., Potter S., Rautanen A., Sawcer S.J., Su Z., Trembath R.C., Viswanathan A.C., Williams N.W., Morris H.R., Donnelly P., Wood N.W. Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum. Mol. Genet. 2011, 20:345-353.
111. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
112. Stamper C., Siegel A., Liang W.S., Pearson J.V., Stephan D.A., Shill H., Connor D., Caviness J.N., Sabbagh M., Beach T.G., Adler C.H., Dunckley T. Neuronal gene expression correlates of Parkinson's disease with dementia. Mov. Disord. 2008, 23:1588-1595.
113. Stranger B.E., Nica A.C., Forrest M.S., Dimas A., Bird C.P., Beazley C., Ingle C.E., Dunning M., Flicek P., Koller D., Montgomery S., Tavare S., Deloukas P., Dermitzakis E.T. Population genomics of human gene expression. Nat. Genet. 2007, 39:1217-1224.
114. Surmeier D.J. Calcium ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol. 2007, 6:933-938.
115. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
116. Tanaka M., Kim Y.M., Lee G., Junn E., Iwatsubo T., Mouradian M.M. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem. 2004, 279:4625-4631.
117. Tarawneh R., Galvin J.E. Distinguishing Lewy body dementias from Alzheimer's disease. Expert Rev. Neurother. 2007, 7:1499-1516.
118. Tong T., Zhao H. Practical guidelines for assessing power and false discovery rate for a fixed sample size in microarray experiments. Stat. Med. 2008, 27:1960-1972.
119. Trabzuni D., Ryten M., Walker R., Smith C., Imran S., Ramasamy A., Weale M.E., Hardy J. Quality control parameters on a large dataset of regionally-dissected human control brains for whole genome expression studies. J. Neurochem. 2011.
120. Uhl G.R., Javitch J.A., Snyder S.H. Normal MPTP binding in parkinsonian substantial nigra: evidence for extraneuronal toxin conversion in human brain. Lancet 1985, 1:956-957.
121. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., Nelson L.M. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 2003, 157:1015-1022.
122. van der Brug M., Nalls M.A., Cookson M.R. Deep sequencing of coding and non-coding RNA in the CNS. Brain Res. 2010, 1338:146-154.
123. Vassar R., Kovacs D.M., Yan R., Wong P.C. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J. Neurosci. 2009, 29:12787-12794.
124. Vogt I.R., Lees A.J., Evert B.O., Klockgether T., Bonin M., Wullner U. Transcriptional changes in multiple system atrophy and Parkinson's disease putamen. Exp. Neurol. 2006, 199:465-478.
125. Wang Z., Gerstein M., Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 2009, 10:57-63.
126. Weis S., Llenos I.C., Dulay J.R., Elashoff M., Martinez-Murillo F., Miller C.L. Quality control for microarray analysis of human brain samples: the impact of postmortem factors, RNA characteristics, and histopathology. J. Neurosci. Methods 2007, 165:198-209.
127. Whitney A.R., Diehn M., Popper S.J., Alizadeh A.A., Boldrick J.C., Relman D.A., Brown P.O. Individuality and variation in gene expression patterns in human blood. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1896-1901.
128. Witte J.S. Prostate cancer genomics: towards a new understanding. Nat. Rev. Genet. 2009, 10:77-82.
129. Wray S., Lewis P.A. A tangled web-tau and sporadic Parkinson's disease. Front Psychiatry 2010, 1:150.
130. Xi L., Feber A., Gupta V., Wu M., Bergemann A.D., Landreneau R.J., Litle V.R., Pennathur A., Luketich J.D., Godfrey T.E. Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res. 2008, 36:6535-6547.
131. Zhang Y., James M., Middleton F.A., Davis R.L. Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 137B:5-16.
132. Zhang Y., Szustakowski J., Schinke M. Bioinformatics analysis of microarray data. Methods Mol. Biol. 2009, 573:259-284.
133. Zheng B., Liao Z., Locascio J.J., Lesniak K.A., Roderick S.S., Watt M.L., Eklund A.C., Zhang-James Y., Kim P.D., Hauser M.A., Grunblatt E., Moran L.B., Mandel S.A., Riederer P., Miller R.M., Federoff H.J., Wullner U., Papapetropoulos S., Youdim M.B., Cantuti-Castelvetri I., Young A.B., Vance J.M., Davis R.L., Hedreen J.C., Adler C.H., Beach T.G., Graeber M.B., Middleton F.A., Rochet J.C., Scherzer C.R. PGC-1α a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med. 2010, 2:52-73.
134. Moran L.B., Croisier E., Duke D.C., Kalaitzakis M.E., Roncaroli F., Deprez M., Dexter D.T., Pearce R.K., Graeber M.B. Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra. Acta Neuropathol. (Berlin) 2007, 113:253-263.
135. Duke D., Moran L., Pearce R., Graeber M. The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability. Neurogenetics 2007, 8:83-94.